Fábio P Sellera1, Miriam R Fernandes2, Caetano P Sabino2,3, Laura M de Freitas4, Luciano C B A da Silva5, Fabio C Pogliani1, Martha S Ribeiro6, Michael R Hamblin7,8, Nilton Lincopan2,9. 1. Department of Internal Medicine, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Orlando M. Paiva, 87, São Paulo, SP, 05508-270, Brazil. 2. Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Orlando M. Paiva, 580, São Paulo, SP, 05508-000, Brazil. 3. BioLambda, Científica e Comercial, LTDA. R. Prof. Teotônio Monteiro de Barros Filho, 532, São Paulo, SP, 05360-030, Brazil. 4. Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, São Paulo State University (UNESP), R. Expedicionários do Brasil, 1621, Araraquara, SP, 14801-902, Brazil. 5. Department of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Orlando M. Paiva 87, São Paulo, SP, 05508-270, Brazil. 6. Center for Lasers and Applications, IPEN-CNEN, Av. Prof. Lineu Prestes, 2242, São Paulo, SP, 05508-000, Brazil. 7. Wellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom St, Boston, MA, 02114, USA. 8. Harvard-Medical School, 25 Shattuck St, Boston, MA, 02115, USA. 9. Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, São Paulo, SP, 05508-900, Brazil.
Abstract
BACKGROUND: Carbapenem-resistant bacterial infections are a critical problem in veterinary medicine with limited treatment options. OBJECTIVE: To describe effective probiotic and photodynamic therapy of a dog with gut colonization and ear infection caused by a hospital-associated lineage of carbapenemase (VIM-2)-producing Pseudomonas aeruginosa. ANIMALS: A 5-year-old Lhasa apso dog presented with otitis externa. METHODS AND MATERIALS: Unilateral otitis externa caused by carbapenem-resistant P. aeruginosa was treated with antimicrobial photodynamic therapy (aPDT) using methylene blue as photosensitizer [wavelength 660 nm, fluence 140 J/cm2 , 8 J and 80 s per point (six equidistant points), 100 mW, spot size 0.028 cm2 and fluence rate 3.5 W/cm2 ]. The isolated bacterial strain also was tested for susceptibility to in vitro aPDT where the survival fraction was quantified by colony forming unit counts after exposure to increasing light doses. For decolonization, probiotic supplements were orally administered (once daily) for 14 days. Effectiveness of probiotics and photodynamic therapy was evaluated by clinical and microbiological culture assays. RESULTS: Complete resolution of clinical signs was achieved by Day 7 after aPDT. Samples collected immediately and after seven and 14 days following aPDT were negative for VIM-2-producing P. aeruginosa. Oral and rectal swabs collected on days 7, 14 and 21 after probiotic therapy, confirmed effective gastrointestinal decolonization. CONCLUSIONS AND CLINICAL IMPORTANCE: Combined use of aPDT and probiotics could be a promising therapeutic strategy for treatment of superficial infections produced by carbapenem-resistant bacteria, while avoiding recurrent infection due to intestinal bacterial carriage of these multidrug-resistant pathogens.
BACKGROUND:Carbapenem-resistant bacterial infections are a critical problem in veterinary medicine with limited treatment options. OBJECTIVE: To describe effective probiotic and photodynamic therapy of a dog with gut colonization and ear infection caused by a hospital-associated lineage of carbapenemase (VIM-2)-producing Pseudomonas aeruginosa. ANIMALS: A 5-year-old Lhasa apso dog presented with otitis externa. METHODS AND MATERIALS: Unilateral otitis externa caused by carbapenem-resistant P. aeruginosa was treated with antimicrobial photodynamic therapy (aPDT) using methylene blue as photosensitizer [wavelength 660 nm, fluence 140 J/cm2 , 8 J and 80 s per point (six equidistant points), 100 mW, spot size 0.028 cm2 and fluence rate 3.5 W/cm2 ]. The isolated bacterial strain also was tested for susceptibility to in vitro aPDT where the survival fraction was quantified by colony forming unit counts after exposure to increasing light doses. For decolonization, probiotic supplements were orally administered (once daily) for 14 days. Effectiveness of probiotics and photodynamic therapy was evaluated by clinical and microbiological culture assays. RESULTS: Complete resolution of clinical signs was achieved by Day 7 after aPDT. Samples collected immediately and after seven and 14 days following aPDT were negative for VIM-2-producing P. aeruginosa. Oral and rectal swabs collected on days 7, 14 and 21 after probiotic therapy, confirmed effective gastrointestinal decolonization. CONCLUSIONS AND CLINICAL IMPORTANCE: Combined use of aPDT and probiotics could be a promising therapeutic strategy for treatment of superficial infections produced by carbapenem-resistant bacteria, while avoiding recurrent infection due to intestinal bacterial carriage of these multidrug-resistant pathogens.
Authors: R Köck; I Daniels-Haardt; K Becker; A Mellmann; A W Friedrich; D Mevius; S Schwarz; A Jurke Journal: Clin Microbiol Infect Date: 2018-04-11 Impact factor: 8.067
Authors: Fábio P Sellera; Miriam R Fernandes; Regina Ruiz; Ana C M Falleiros; Fernanda P Rodrigues; Louise Cerdeira; Nilton Lincopan Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790
Authors: Wei Yee Chan; Elizabeth E Hickey; Manouchehr Khazandi; Stephen W Page; Darren J Trott; Peter B Hill Journal: Vet Dermatol Date: 2018-01-24 Impact factor: 1.589
Authors: Meire M Silva; Miriam R Fernandes; Fábio P Sellera; Louise Cerdeira; Lylian K G Medeiros; Felício Garino; Sérgio S Azevedo; Nilton Lincopan Journal: Diagn Microbiol Infect Dis Date: 2018-06-22 Impact factor: 2.803
Authors: Mark Wainwright; Tim Maisch; Santi Nonell; Kristjan Plaetzer; Adelaide Almeida; George P Tegos; Michael R Hamblin Journal: Lancet Infect Dis Date: 2016-11-22 Impact factor: 25.071
Authors: Claire L Gorrie; Mirjana Mirceta; Ryan R Wick; David J Edwards; Nicholas R Thomson; Richard A Strugnell; Nigel F Pratt; Jill S Garlick; Kerri M Watson; David V Pilcher; Steve A McGloughlin; Denis W Spelman; Adam W J Jenney; Kathryn E Holt Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Silvia I Cazorla; Carolina Maldonado-Galdeano; Ricardo Weill; Juan De Paula; Gabriela D V Perdigón Journal: Front Microbiol Date: 2018-04-16 Impact factor: 5.640
Authors: Miriam R Fernandes; Fábio P Sellera; Quézia Moura; Marcelo P N Carvalho; Paula N Rosato; Louise Cerdeira; Nilton Lincopan Journal: Emerg Infect Dis Date: 2018-06 Impact factor: 6.883